Innate Pharma (IPHA) said Thursday that Sanofi (SNY) has agreed to subscribe to about 8.3 million shares of Innate at a price of 1.7974 euros ($2.05) per share for a capital increase of about 15 million euros.
The investment will be used for general corporate purposes, including extending the biotech firm's cash runway, said Innate Chief Executive Jonathan Dickinson.
The deal is expected to close on Friday, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。